NCT01730833View on ClinicalTrials.gov

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 17, 2013

Primary Completion Date

January 12, 2021

Study Completion Date

May 20, 2026

Conditions
HER2-positive Breast CancerRecurrent Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerBreast AdenocarcinomaInflammatory Breast Carcinoma
Interventions
BIOLOGICAL

pertuzumab

Given IV

BIOLOGICAL

trastuzumab

Given IV

DRUG

paclitaxel albumin-stabilized nanoparticle formulation

Given IV

OTHER

laboratory biomarker analysis

Optional correlative studies

Trial Locations (3)

91010

City of Hope Medical Center, Duarte

91030

City of Hope- South Pasadena Cancer Center, South Pasadena

93534

City of Hope Antelope Valley, Lancaster

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01730833 - Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer | Biotech Hunter | Biotech Hunter